Open AccessPharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia
Author(s) -
Daoud AlBadriyeh,
Monica A. Slavin,
Danny Liew,
Karin Thursky,
M. Downey,
A. Grigg,
Ashish Bajel,
K. Stewart,
David C. M. Kong
Publication year - 2010
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkq076
Subject(s) - posaconazole , voriconazole , medicine , myeloid leukaemia , antifungal , myeloid , dermatology
Voriconazole and posaconazole are used prophylactically against invasive fungal infection (IFI) in patients with acute myeloid leukaemia (AML). The current study attempted to evaluate the economics of voriconazole versus posaconazole for prophylaxis in AML.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom